Introduction:

According to the World Health Organization, Human Immunodeficiency Virus (HIV) continues being one of the world's major public health problems. Currently, the importance of adherence to treatment continues being the focus of attention of health professionals. Lack of adherence is a major economic and health problem.

Method:

This study focuses on the pharmaceutical care service performed on all HIV patients (naive and non-naive) on treatment with the coformulated tablet dolutegravir/lamivudine (DTG/3TC) from its commercialization in July 2019 until May 2021. Variables studied: sex, age, adherence, viral load, CD4 lymphocyte count, previous antiretroviral therapy (ART) in non-naïve patients, concomitant treatments, interactions, the reason that led to the change of ART in non-naïve patient and the adverse effects developed.

Results:

In the first interview with the pharmacist in the pharmaceutical care service, five fundamental aspects are discussed: adherence, adverse effects, concomitant treatments and/or herbal products, interactions and reason for changing antiretroviral drugs in non-naive patients. 62 patients started treatment with DTG/3TC: 24.1% (15/62) naive and 75.8% (47/62) no naive. 100% of naive patients were highly adherent, only 6.4% of pre-treated patients were identified as non-adherent. Only one contraindication was found: hypericum.

Conclusions:

Patients are highly adherent, the treatment is effective and safe. The pharmaceutical care service is carried out efficiently. We are aware of our patients' adherence and carry out close pharmacotherapeutic monitoring.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )